Diagnostics

Journal Browser

► Journal Browser

Prognostic and Predictive Biomarkers of Lung Cancer

Share This Special Issue

Special Issue Editor

Dr. Diego Kauffmann-Guerrero

E-Mail Website
Guest Editor

Divison of Respiratory Medicine and Thoracic Oncology, Department of Internal Medicine V and Thoracic Oncology Centre Munich (TOM), Hospital of the University of Munich (LMU), 80336 Munich, Germany
Interests: clinical oncology; lung diseases; metastasis; cancer biology; cancer biomarkers; cancer diagnostics; tumor biology; cancer cell biology; cell signaling; apoptosis

Special Issue Information

Dear Colleagues,

Biomarkers are essential components in diagnosing a disease or pathogenic process, monitoring patients, and provide prognosis for patients. Despite many advances in diagnosis and treatment, lung cancer remains the greatest cause of cancer-related death worldwide. Therefore, reliable biomarkers are needed to guide an optimal treatment sequence for any patient. Predictive and prognostic biomarkers of lung cancer are of significant therapeutic value as well in early detection and follow-up as in advanced diseases.

To date, many predictive and prognostic biomarkers for lung cancer have been proposed. However, only a few of these have achieved significance in clinical practice.

This Special Issue will be focused on Prognostic and Predictive Biomarkers of Lung Cancer, covering a wide variety of possible approaches ranging from biomaterial-based markers, over clinical patient characteristics to imaging.

Dr. Diego Kauffmann-Guerrero
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

biomarkers
personalized medicine
molecular signatures
prognosis
predictive diagnostics
prognostic diagnostics
genetic biomarkers
blood analysis
liquid biopsy
imaging, lung cancer

Published Papers (2 papers)

Download All Papers

Research

Jump to: Other

18 pages, 11775 KiB

Open AccessArticle

Immunofluorescence-Based Assay for High-Throughput Analysis of Multidrug Resistance Markers in Non-Small Cell Lung Carcinoma Patient-Derived Cells

by Jelena Dinić, Ana Podolski-Renić, Miodrag Dragoj, Sofija Jovanović Stojanov, Ana Stepanović, Ema Lupšić, Milica Pajović, Mirna Jovanović, Dušica Petrović Rodić, Dragana Marić, Maja Ercegovac and Milica Pešić

Diagnostics 2023, 13(24), 3617; https://doi.org/10.3390/diagnostics13243617 - 7 Dec 2023

Viewed by 1101

Abstract

Lung cancer remains the leading cause of cancer death globally, with non-small cell lung cancer (NSCLC) accounting for the majority of cases. Multidrug resistance (MDR), often caused by ATP-binding cassette (ABC) transporters, represents a significant obstacle in the treatment of NSCLC. While genetic profiling has an important role in personalized therapy, functional assays that measure cellular responses to drugs are gaining in importance. We developed an automated microplate-based immunofluorescence assay for the evaluation of MDR markers ABCB1, ABCC1, and ABCG2 in cells obtained from NSCLC patients through high-content imaging and image analysis, as part of a functional diagnostic approach. This assay effectively discriminated cancer from non-cancer cells within mixed cultures, which is vital for accurate assessment of changes in MDR marker expression in different cell populations in response to anticancer drugs. Validation was performed using established drug-sensitive (NCI-H460) and drug-resistant (NCI-H460/R) NSCLC cell lines, demonstrating the assay’s capacity to distinguish and evaluate different MDR profiles. The obtained results revealed wide-ranging effects of various chemotherapeutic agents on MDR marker expression in different patient-derived NSCLC cultures, emphasizing the need for MDR diagnostics in NSCLC. In addition to being a valuable tool for assessing drug effects on MDR markers in different cell populations, the assay can complement genetic profiling to optimize treatment. Further assay adaptations may extend its application to other cancer types, improving treatment efficacy while minimizing the development of resistance. Full article

(This article belongs to the Special Issue Prognostic and Predictive Biomarkers of Lung Cancer)

► Show Figures

Graphical abstract

Other

Jump to: Research

15 pages, 1806 KiB

Open AccessSystematic Review

Prognostic Role of KRAS G12C Mutation in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

by Durgesh Wankhede, Christophe Bontoux, Sandeep Grover and Paul Hofman

Diagnostics 2023, 13(19), 3043; https://doi.org/10.3390/diagnostics13193043 - 25 Sep 2023

Cited by 1 | Viewed by 1233

Abstract

KRAS G12C mutation (mKRAS G12C) is the most frequent KRAS point mutation in non-small cell lung cancer (NSCLC) and has been proven to be a predictive biomarker for direct KRAS G12C inhibitors in advanced solid cancers. We sought to determine the prognostic significance of mKRAS G12C in patients with NSCLC using the meta-analytic approach. A protocol is registered at the International Prospective Register for systematic reviews (CRD42022345868). PubMed, EMBASE, The Cochrane Library, and Clinicaltrials.gov.in were searched for prospective or retrospective studies reporting survival data for tumors with mKRAS G12C compared with either other KRAS mutations or wild-type KRAS (KRAS-WT). The hazard ratios (HRs) for overall survival (OS) or Disease-free survival (DFS) of tumors were pooled according to fixed or random-effects models. Sixteen studies enrolling 10,153 participants were included in the final analysis. mKRAS G12C tumors had poor OS [HR, 1.42; 95% CI, 1.10–1.84, p = 0.007] but similar DFS [HR 2.36, 95% CI 0.64–8.16] compared to KRAS-WT tumors. Compared to other KRAS mutations, mKRAS G12C tumors had poor DFS [HR, 1.49; 95% CI, 1.07–2.09, p < 0.0001] but similar OS [HR, 1.03; 95% CI, 0.84–1.26]. Compared to other KRAS mutations, high PD-L1 expression (>50%) [OR 1.37 95% CI 1.11–1.70, p = 0.004] was associated with mKRAS G12C tumors. mKRAS G12C is a promising prognostic factor for patients with NSCLC, negatively impacting survival. Prevailing significant heterogeneity and selection bias might reduce the validity of these findings. Concomitant high PD-L1 expression in these tumors opens doors for exciting therapeutic potential. Full article

(This article belongs to the Special Issue Prognostic and Predictive Biomarkers of Lung Cancer)

► Show Figures